Afectación renal por fármacos, medios diagnósticos y tóxicos

  1. Martínez Miguel, P. 1
  2. Fernández Rodríguez, M.L. 1
  3. Hernández Sevillano, B. 2
  4. Begoña Boldoba, N. 2
  5. Castillo Torres, C. 3
  1. 1 Servicios de Nefrología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España
  2. 2 Servicio de Nefrología, Hospital Universitario de Guadalajara, Guadalajara, España
  3. 3 Servicios de Anatomía Patológica, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España
Montrer des affiliations +
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2023

Titre de la publication: Enfermedades nefrourinarias (IV): El riñón en las enfermedades sistémicas. Síndrome hepatorrenal

Serie: 13

Número: 82

Pages: 4850-4857

Type: Article

DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Some drugs, diagnostic media and toxic substances can cause structural kidney damage, with a negative effect on their function. This is fundamentally because the kidneys are highly vascularized organs and the main means of eliminating many metabolites. Furthermore, the urinary concentration process means that these substances may accumulate in the tubules and interstices, leading to lesions at this level. In general, non-specific harm is caused in the tubulointerstitial parenchyma, with three characteristic lesion patterns: acute interstitial nephritis, chronic interstitial nephritis and acute tubular necrosis. Vascular or glomerular damage occurs less often. To prevent this pathology it is necessary to know which components can be nephrotoxic and how we should use them in patients who are at risk. Withdrawal of the toxic agent is the key to resolving the symptoms.

Références bibliographiques

  • Sanz Martín N, Martínez Miguel P. Afectación renal por fármacos, medios diagnósticos y tóxicos. Medicine. 2019;12(82):4840-48.
  • Rodríguez Palomares JR, Liaño García F, Tenorio Cañamas MT, De Arriba G. Fracaso renal agudo. Concepto, definición, epidemiología, etiopatogenia y clasificación, manifestaciones clínicas, complicaciones y diagnóstico diferencial. Mecicine. 2015;11 (81):4842-51.
  • Anaya Fernández S, Rivera Hernández F, de Arriba de la Fuente G. Nefropatías intersticiales. Medicine. 2011;10(80):5405-11.
  • Praga M, Sevillano A, Aunón P, González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015;30(9):1472-9.
  • Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900.
  • Praga M, González E. Acute interstitial nephritis. Kidney Int 2010; 77:956.
  • Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102:459.
  • Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int. 1992;41:1588.
  • Heyman SN, Stillman IE, Brezis M, Epstein FH, Spokes K, Rosen S. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J Am Soc Nephrol. 1993;4(1):69-80.
  • Launay Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84.
  • Luke DR, Vadiei K, López Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 1992;7:1.
  • SaitoY, Okamoto K, Kobayashi M, Narumi K, Yamada T, Iseki K. Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters. Eur J Pharmacol. 2017;811:191-8.
  • Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol. 2020;31:435.
  • Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073-126.
  • Fortin MC, Raymond MA, Madore F, Fugère JA, Pâquet M, St Louis G. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant. 2004;4:946-52.
  • Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int. 1993;43:706.
  • Sierra F, Suárez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545-53.
  • Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med. 1988;319:689-98.
  • Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989; 35:1257.
  • Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis. 2012;60:82.
  • Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77:219.
  • Sabath E, Robles Osorio ML. Renal health and the environment: heavy metal nephrotoxicity. Nefrologia. 2012;32(3):279-86.
  • Hellström L, Elinder CG, Dahlberg B, Lundberg M, Järup L, Persson B. Cadmium exposure and end-stage renal disease. Am J Kidney Dis. 2001;38(5):1001-8.
  • Lin JL, Yu CC, LinTan DT, Ho HH. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int. 2001;60(1):266-71.
  • Chakera A, Lasserson D, Beck LH Jr, Roberts IS, Winearls CG. Membranous nephropathy after use of UK-manufactured skin creams containing mercury. QJM. 2011;104(10):893-6.
  • Huang M, Choi SJ, Kim DW, Kim NY, Park CH, Yu SD. Risk assessment of low-level cadmium and arsenic on the kidney. J Toxicol Environ Health. 2009;72(21-22):1493-8.
  • Mansoor K, Kheetan M, Shahnawaz S, Shapiro AP, Patton Tackett E, Dial L. Systematic review of nephrotoxicity of drugs of abuse, 2005-2016. BMC Nephrol. 2017;18(1):379.
  • Gökmen MR, Cosyns JP, Arlt VM, Stiborová M, Phillips DH, Schmeiser HH. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med. 2013;158(6):469-77.
  • Vanherweghem JL, Abramowicz D, Tielemans C, Depierreux M. Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. Am J Kidney Dis. 1996; 27(2):209-15.
  • Saviuc P, Danel V. New syndromes in mushroom poisoning. Toxicol Rev. 2006;25(3):199-209.
La source de données: Dialnet